Q2 2026 saw stable EBITDA and revenue growth, with strong segment volumes but higher costs and a NOK 337 million impairment on Alginor. A cost-saving program and selective price adjustments are underway amid ongoing market and energy uncertainties.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.